Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela™ (delafloxacin) across all its MENA markets. In addition, Hikma has the right of first negotiation for all other products in Melinta’s portfolio and pipeline in the region.
Baxdela™ is a novel antibiotic product used for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Baxdela™ is a fluoroquinolone with demonstrated efficacy against both gram-positive and gram-negative pathogens, including MRSA (methicillin-resistant Staphylococcus aureus). Baxdela™ was approved by the US Food and Drug Administration (FDA) in 2017.
Hikma is a leading provider of antibiotics in the MENA region, offering a wide range of products to doctors and pharmacists. As Antimicrobial Resistance (AMR) continues to pose treatment challenges for healthcare professionals, offering this new, innovative product in the region will arm them with new ways to combat this growing threat.
Mazen Darwazah, Executive Vice Chairman and President of MENA said, “We are very pleased to establish a partnership with Melinta and to be able to bring this innovative product to the region. As the challenge of AMR grows, we have an important role to play in helping to equip doctors here in MENA with the latest and most innovative developments.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.